CDA | Evidence Driven
CDA | Evidence Driven

Avastin for Platinum-Resistant Ovarian Cancer – Details

Details

Files
Generic Name:
Bevacizumab
Project Status:
Complete
Therapeutic Area:
Platinum Resistant Ovarian Cancer
Manufacturer:
Hoffmann-La -Roche Limited
Brand Name:
Avastin
Project Line:
Reimbursement Review
Project Number:
PC0066-000
NOC Status at Filing:
Post NOC
Performance Metric:
Achieved
Strength:
25mg/mL
Tumour Type:
Gynecology
Indications:
Platinum-Resistant Ovarian Cancer
Funding Request:
In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan, for the treatment of patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer
Sponsor:
Hoffmann-La -Roche Limited
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Requested and Not Granted
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:

Files

Provincial Funding Summary View PDF
Bevacizumab (Avastin) Platinum-Resistant Ovarian Cancer – pERC Final Recommendation Final Recommendation May 5, 2016 View PDF
Bevacizumab (Avastin) Platinum-Resistant Ovarian Cancer – Final Economic Guidance Report Guidance Reports May 5, 2016 View PDF
Bevacizumab (Avastin) Platinum-Resistant Ovarian Cancer – Final Clinical Guidance Report Guidance Reports May 5, 2016 View PDF
Bevacizumab (Avastin) Platinum-Resistant Ovarian Cancer - Initial pERC Recommendation Initial Recommendation March 3, 2016 View PDF
PAG Feedback on Initial Recommendation Feedback May 5, 2016 View PDF
Manufacturer Feedback on Initial Recommendation Feedback May 5, 2016 View PDF
Patient Advocacy Group Feedback on Initial Recommendation Feedback May 5, 2016 View PDF
Bevacizumab (Avastin) Platinum-Resistant Ovarian Cancer – Patient Advocacy Group COI Declarations COI Declarations May 5, 2016 View PDF

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.

Last Updated : August 15, 2016